Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 107

Similar articles for PubMed (Select 21349983)

1.

Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile.

Babakhani F, Gomez A, Robert N, Sears P.

J Med Microbiol. 2011 Aug;60(Pt 8):1213-7. doi: 10.1099/jmm.0.029470-0. Epub 2011 Feb 24.

2.

Fidaxomicin inhibits toxin production in Clostridium difficile.

Babakhani F, Bouillaut L, Sears P, Sims C, Gomez A, Sonenshein AL.

J Antimicrob Chemother. 2013 Mar;68(3):515-22. doi: 10.1093/jac/dks450. Epub 2012 Dec 2.

3.

Postantibiotic effect of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile.

Babakhani F, Gomez A, Robert N, Sears P.

Antimicrob Agents Chemother. 2011 Sep;55(9):4427-9. doi: 10.1128/AAC.00104-11. Epub 2011 Jun 27.

4.

Antimicrobial activities of fidaxomicin.

Goldstein EJ, Babakhani F, Citron DM.

Clin Infect Dis. 2012 Aug;55 Suppl 2:S143-8. doi: 10.1093/cid/cis339.

5.

Fidaxomicin inhibits spore production in Clostridium difficile.

Babakhani F, Bouillaut L, Gomez A, Sears P, Nguyen L, Sonenshein AL.

Clin Infect Dis. 2012 Aug;55 Suppl 2:S162-9. doi: 10.1093/cid/cis453.

6.

Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection.

Goldstein EJ, Citron DM, Sears P, Babakhani F, Sambol SP, Gerding DN.

Antimicrob Agents Chemother. 2011 Nov;55(11):5194-9. doi: 10.1128/AAC.00625-11. Epub 2011 Aug 15.

7.

In vitro selection, via serial passage, of Clostridium difficile mutants with reduced susceptibility to fidaxomicin or vancomycin.

Leeds JA, Sachdeva M, Mullin S, Barnes SW, Ruzin A.

J Antimicrob Chemother. 2014 Jan;69(1):41-4. doi: 10.1093/jac/dkt302. Epub 2013 Jul 25.

8.

Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection.

Citron DM, Babakhani F, Goldstein EJ, Nagaro K, Sambol S, Sears P, Shue YK, Gerding DN.

Anaerobe. 2009 Dec;15(6):234-6. doi: 10.1016/j.anaerobe.2009.09.005. Epub 2009 Sep 12.

PMID:
19755166
9.

Both fidaxomicin and vancomycin inhibit outgrowth of Clostridium difficile spores.

Allen CA, Babakhani F, Sears P, Nguyen L, Sorg JA.

Antimicrob Agents Chemother. 2013 Jan;57(1):664-7. doi: 10.1128/AAC.01611-12. Epub 2012 Nov 12.

10.

Fidaxomicin: a novel macrocyclic antibiotic for the treatment of Clostridium difficile infection.

Crawford T, Huesgen E, Danziger L.

Am J Health Syst Pharm. 2012 Jun 1;69(11):933-43. doi: 10.2146/ajhp110371. Review.

PMID:
22610025
11.

Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection.

Nerandzic MM, Mullane K, Miller MA, Babakhani F, Donskey CJ.

Clin Infect Dis. 2012 Aug;55 Suppl 2:S121-6. doi: 10.1093/cid/cis440.

12.

Bactericidal activity of telavancin, vancomycin and metronidazole against Clostridium difficile.

Goldstein EJ, Citron DM, Tyrrell KL, Warren YA.

Anaerobe. 2010 Jun;16(3):220-2. doi: 10.1016/j.anaerobe.2009.12.002. Epub 2010 Jan 4.

PMID:
20044011
13.

Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain.

Petrella LA, Sambol SP, Cheknis A, Nagaro K, Kean Y, Sears PS, Babakhani F, Johnson S, Gerding DN.

Clin Infect Dis. 2012 Aug;55(3):351-7. doi: 10.1093/cid/cis430. Epub 2012 Apr 20.

14.

Fidaxomicin: in Clostridium difficile infection.

Duggan ST.

Drugs. 2011 Dec 24;71(18):2445-56. doi: 10.2165/11208220-000000000-00000.

PMID:
22141387
15.

Fidaxomicin for the treatment of Clostridium difficile infections.

Whitman CB, Czosnowski QA.

Ann Pharmacother. 2012 Feb;46(2):219-28. doi: 10.1345/aph.1Q481. Epub 2012 Feb 7. Review.

PMID:
22318930
16.

Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI.

Louie TJ, Cannon K, Byrne B, Emery J, Ward L, Eyben M, Krulicki W.

Clin Infect Dis. 2012 Aug;55 Suppl 2:S132-42. doi: 10.1093/cid/cis338.

17.

Fidaxomicin versus vancomycin for Clostridium difficile infection.

Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, Gorbach S, Sears P, Shue YK; OPT-80-003 Clinical Study Group.

N Engl J Med. 2011 Feb 3;364(5):422-31. doi: 10.1056/NEJMoa0910812.

18.

Investigations of the mode of action and resistance development of cadazolid, a new antibiotic for treatment of Clostridium difficile infections.

Locher HH, Caspers P, Bruyère T, Schroeder S, Pfaff P, Knezevic A, Keck W, Ritz D.

Antimicrob Agents Chemother. 2014;58(2):901-8. doi: 10.1128/AAC.01831-13. Epub 2013 Nov 25.

19.

Fidaxomicin attains high fecal concentrations with minimal plasma concentrations following oral administration in patients with Clostridium difficile infection.

Sears P, Crook DW, Louie TJ, Miller MA, Weiss K.

Clin Infect Dis. 2012 Aug;55 Suppl 2:S116-20. doi: 10.1093/cid/cis337.

20.

In vitro activities of daptomycin, vancomycin, and penicillin against Clostridium difficile, C. perfringens, Finegoldia magna, and Propionibacterium acnes.

Tyrrell KL, Citron DM, Warren YA, Fernandez HT, Merriam CV, Goldstein EJ.

Antimicrob Agents Chemother. 2006 Aug;50(8):2728-31.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk